Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $4.26B
• Dividend Yield: N/A
• Average Volume (3M): 920.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: N/A
• EPS Growth: -21.96%
• Country: US
• Employees: 437
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.29
• Shares Outstanding: 104,705,330
• 10 Day Avg. Volume: 764,595
• 30 Day Avg. Volume: 920,948
• PEG Ratio: -0.28
• Price to Book (P/B): 4.41
• Price to Sales (P/S): 807.81
• P/FCF Ratio: -11.41
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 749.04
• Enterprise Value/Gross Profit: 690.56
• Enterprise Value/Ebitda: -8.09
• 1Y Price Target: $88.00
• Price Target Upside: 116.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -4.94
• Revenue Forecast (FY): $61.62M

• Rating: 55 Neutral
• Price Target: $45.00 ▲(10.62% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by very large losses and heavy cash burn, with near-term technical momentum also weak. These are partly offset by a constructive earnings-call outlook—early commercial traction, meaningful pipeline/regulatory progress, and a strengthened cash runway following the January 2026 financing—while valuation signals provide limited clarity due to negative earnings and no dividend.

Positive Factors

Strong Balance Sheet / Runway

A multi-year cash runway into 2030 materially reduces near-term financing and dilution risk for this clinical-stage biopharma. It gives management flexibility to fund commercialization of PALSONIFY, advance multiple pivotal trials, and scale infrastructure without immediate capital raises.

Commercial Launch Momentum

Early commercial adoption across community and pituitary centers, coupled with formulary wins, indicates initial product-market fit and establishes distribution and payer relationships. These durable commercial capabilities form the foundation for recurring product revenue as uptake and reimbursement normalize.

De-risking Late-stage Pipeline

Robust biomarker and early clinical signals for atumelnant plus initiation of global Phase II/III materially de-risks a lead program. Successful late-stage data would diversify revenue potential beyond a single product and strengthen long-term franchise value in endocrine disorders.

Negative Factors

Very High Cash Burn and Losses

Sustained large operating losses and negative free cash flow make the business reliant on capital markets or partnerships over time. Heavy burn magnifies dilution risk if commercial ramp or trial progress slips, and reduces margin for error on execution across multiple development programs.

Revenue Small vs Cost Base / High Expense Guidance

Very modest current product revenue versus planned high operating spend implies a long path to breakeven and high sensitivity to launch execution. If revenues fail to scale as projected, management will need to slow programs or raise capital, both of which can impair long-term growth trajectories.

Reimbursement & Launch Uncertainty

Persistent payer friction and reliance on bridge programs slow durable revenue conversion and complicate forecasting. Extended reimbursement cycles reduce lifetime patient adherence and sales predictability, increasing the risk that commercial scale-up takes longer and costs more than modeled.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

How the Company Makes Money

Crinetics Pharmaceuticals generates revenue through a combination of grants, collaborations, and potential product sales. The company typically engages in strategic partnerships with larger pharmaceutical companies to co-develop its drug candidates, which can provide upfront payments and milestone payments as clinical and regulatory milestones are achieved. Additionally, once products receive regulatory approval, the company can earn revenue through sales in the market. Moreover, Crinetics may also receive royalties from its partners based on sales of products developed through their collaborations, thereby diversifying its revenue streams.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Despite strong gross margins on limited sales, profitability and cash generation are very weak: 2025 net loss was roughly $465M on ~$5.4M revenue and operating cash flow was about -$378M (FCF ~-$384M). The balance sheet is a relative strength with modest leverage, but ongoing losses and heavy cash burn elevate financing/dilution risk over time.

Income Statement

Revenue is small but volatile, with a sharp jump in 2025 (+253% YoY) after a weak 2024, indicating an early/uneven commercial profile. Gross profit is strong in recent years (near ~80–100% gross margin in 2021–2025), but profitability is deeply negative: 2025 net loss was roughly $465M on ~$5.4M revenue (very large negative net margin), and operating losses widened versus 2024. Overall, the company shows improving top-line potential but remains heavily loss-making with limited operating leverage today.

Balance Sheet

Leverage is modest, with debt-to-equity staying low (roughly ~4–10% in 2023–2025 and near ~1% in 2021–2022), which reduces balance-sheet risk. However, equity declined in 2025 versus 2024, consistent with continued losses, and returns on equity are materially negative across the period. Net-net: a relatively clean, low-debt balance sheet, but ongoing losses are eroding shareholder value over time.

Cash Flow

Cash burn is significant and worsening: operating cash flow was about -$378M in 2025 versus about -$226M in 2024, with free cash flow similarly negative (~-$384M in 2025). Free cash flow broadly tracks net losses (free cash flow roughly in line with net income losses), suggesting limited non-cash offsets and a business still reliant on funding to sustain operations. The recent uptick in free-cash-flow growth is not enough to offset the magnitude of the outflows.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.42M	1.04M	4.01M	4.74M	1.08M
Gross Profit	4.34M	1.04M	4.01M	4.74M	1.08M
EBITDA	-461.25M	-336.07M	-221.51M	-166.90M	-106.78M
Net Income	-465.32M	-298.41M	-214.53M	-163.92M	-107.64M
Balance Sheet
Total Assets	1.13B	1.43B	635.35M	352.18M	351.01M
Cash, Cash Equivalents and Short-Term Investments	1.03B	1.35B	558.55M	334.43M	333.71M
Total Debt	48.54M	51.72M	51.73M	3.08M	3.07M
Total Liabilities	134.17M	109.79M	96.25M	35.85M	19.07M
Stockholders Equity	992.08M	1.32B	539.11M	316.33M	331.94M
Cash Flow
Free Cash Flow	-383.68M	-229.81M	-171.00M	-116.86M	-89.02M
Operating Cash Flow	-377.92M	-225.97M	-166.31M	-115.20M	-88.59M
Investing Cash Flow	173.91M	-574.82M	-200.41M	-173.98M	-56.48M
Financing Cash Flow	40.61M	1.01B	388.94M	121.96M	252.68M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Negative. The current price of 40.68 is below the 20-day moving average (MA) of 44.83, below the 50-day MA of 48.59, and above the 200-day MA of 39.20, indicating a neutral trend. The MACD of -2.08 indicates Positive momentum. The RSI at 31.51 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	70 Outperform	$4.04B	34.71	13.47%	―	64.83%	-9.12%
KYMR	64 Neutral	$7.36B	―	-25.78%	―	-50.05%	-54.47%
APLS	56 Neutral	$2.65B	167.61	7.48%	―	42.11%	―
CRNX	55 Neutral	$4.26B	―	-40.17%	―	―	-21.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RARE	46 Neutral	$2.22B	-3.94	-656.54%	―	20.63%	8.09%

Crinetics Pharmaceuticals Corporate Events

Crinetics Highlights Breakout Year and Strong Endocrinology Pipeline

On January 13, 2026, Crinetics Pharmaceuticals’ founder and CEO Scott Struthers presented a company update at the 44th annual J.P. Morgan Healthcare Conference in San Francisco, highlighting 2025 as a breakout year in which the company launched PALSONIFY (paltusotine) commercially in the U.S., reported early signs of market uptake, and advanced its strategy to become a leading endocrinology-focused pharmaceutical business. The update emphasized a late-stage pipeline of potentially transformative assets, including paltusotine for additional indications such as carcinoid syndrome, atumelnant for adult and pediatric congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682 for neuroendocrine and other SST2+ tumors, supported by positive Phase 2 data, initiation of multiple Phase 3 and Phase 1/2 studies, and a strong preliminary and unaudited liquidity position of roughly $1.4 billion in cash, cash equivalents and investments as of early January 2026, positioning the company to fund operations and development programs well into the next decade.

The most recent analyst rating on (CRNX) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Crinetics Announces Major Public Offering to Fund Growth

On January 6, 2026, Crinetics Pharmaceuticals entered into an underwriting agreement with a syndicate led by Leerink Partners and J.P. Morgan Securities for an underwritten public offering of 7,620,000 shares of common stock at a public price of $45.95 per share, with underwriters purchasing at $43.42275 per share. The deal, which includes a 30-day option for underwriters to buy up to an additional 1,143,000 shares, is expected to close on January 8, 2026 and is expected to generate approximately $330.2 million in net proceeds, or about $379.8 million if the option is fully exercised, providing Crinetics with substantial capital to fund the commercial launch of PALSONIFY, advance its research and development pipeline, and support broader corporate purposes, thereby strengthening its financial position as it scales its endocrine-focused portfolio.

The most recent analyst rating on (CRNX) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Crinetics Highlights Strong PALSONIFY Launch and Trial Progress

On January 5, 2026, Crinetics Pharmaceuticals reported strong early U.S. launch metrics for PALSONIFY, its recently FDA-approved first-line acromegaly treatment, including unaudited preliminary net product revenue of more than $5 million in the fourth quarter of 2025, over 200 patient enrollment forms, more than 125 unique prescribers split evenly between community and pituitary centers, and favorable reimbursement dynamics with many prescriptions filled without bridge supplies and prior authorizations typically lasting 12 months. At the same time, the company released positive topline data from the fourth cohort and open-label extension of its Phase 2 TouCAHn trial of atumelnant in adults with classic congenital adrenal hyperplasia, showing a 67% mean reduction in androstenedione levels and successful glucocorticoid dose reduction to physiologic levels in most completers, alongside a favorable safety profile with no serious or treatment-related severe adverse events and no hepatic transaminase issues, reinforcing the candidate’s potential to strengthen Crinetics’ endocrine portfolio and future market positioning in CAH and ACTH-driven disorders.

The most recent analyst rating on (CRNX) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.